Full-Time

Global Regulatory Lead

Posted on 5/7/2025

Deadline 9/5/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$172.5k - $249.2k/yr

Senior, Expert

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

In Person

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Direct strategic regulatory leadership experience in clinical development of drugs and/or innovative biologics products
  • Direct experience using appropriate interpersonal styles and techniques to build internal networks and lead complex negotiations with internal and external stakeholders
  • Highly effective communication skills, specifically excellent oral and written presentation skills
  • Organizational understanding; self-motivated and able to work in a highly matrixed structure including sharing knowledge with relevant stakeholders
  • Strong sensitivity for a multicultural/multinational environment
  • Proven leader of groups and teams
  • BS/BA degree in a relevant scientific discipline required
  • At least 12+ years of relevant pharmaceutical/biotechnology experience in R&D, including at least 10 years of relevant Regulatory Affairs experience (regional and/or global), in early and late development
  • Demonstrated expert regulatory strategic experience and understanding of the regulatory environment to develop regulatory strategies
  • Ability to work strategically within a sophisticated, business critical and high-profile development program
  • Experience being accountable for developing and defending innovative regulatory strategies at Global Project Teams or equivalent forum
  • Previous experience in leading Health Authority interactions in major markets
  • Strategic regulatory leadership expertise with experience in developing and implementing successful regulatory strategy and with preparation of (s)BLA, (s)NDA, or MAA, INDs, Health Authority meeting briefing documents and negotiating with a national/regional Health Authority within a major market (e.g. US, EU)
  • Experience leading filings/registrations and obtaining a regulatory action in a major market(s)
  • Project leadership experience
  • Experience leading a team and/or developing internal talent
Responsibilities
  • Accountable for leading the development and execution of innovative and value-added global regulatory strategies and be responsible for formulating the Global Regulatory Project Strategy (GRPS), Global Submission Strategy, and core product labeling in development as well as for life cycle management of products
  • Responsible for proactively contributing to the Target Product Profile (TPP), ensuring competitive profiles in alignment with the business objectives
  • Accountable for leading the GRT for fostering team performance by aligning team on mission, prioritization, objectives, and setting clear expectations for the Global Regulatory Strategy and Plan, including a global labeling strategy for assigned projects
  • The role will supervise, coach, and facilitate a feedback culture within the GRT to develop team performance
  • The GRL is expected to develop a team of Regulatory Strategists (RS) as appropriate
  • The GRL is accountable for ensuring alignment and communication internally and externally as 'one GRA voice' with TA, GBU Head and up to the GRA LT when needed to advocate regulatory position to governance and committees and shares outcomes to GRT and cross-functional partners as appropriate
  • Identify opportunities of regulatory acceleration, take thoughtful risks, accept challenges, and making final decisions on the regulatory success rates and mitigations on behalf of the GRT
  • The GRL is the single GRA point of contact for the program and represents GRA at the GPT / GBT and internal governance committees
  • The role is responsible for assessing and interpreting the global regulatory and competitive environments and accountable to ensure that it leverages expertise in commercial competitive intelligence and other parts of GRA (e.g. Regional experts and Regulatory Science and Policy) in order to ensure the most robust strategy possible and is accountable for determining any updates to the regulatory strategy accordingly
  • Leads development of global HA interaction plan and strategy in collaboration with GRT. Is accountable for the communication of the key outcomes to senior management
  • Advances the organization’s goals by participating and taking leadership roles in professional associations, industry and trade groups as appropriate for assigned therapeutic area and projects in collaboration with the Regions
  • Accountable for regulatory assessment for Due Diligence activities as applicable through the partnership with GRA Strategy and Business Optimization
Desired Qualifications
  • Advanced degree (PharmD, PhD, MD or DVM or MSc in Biology, Life Science, or related field) is preferred

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing extensive research and development to create new therapies and improve existing ones, ensuring they meet the needs of patients and healthcare providers. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines, over-the-counter products, and vaccines. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The FDA approval of Dupixent addresses a large unmet need in dermatology.
  • Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.

What critics are saying

  • Increased competition in immunology could impact Sanofi's market share.
  • Potential delays in regulatory approvals may affect new product launches.
  • Integration challenges from acquisitions could disrupt operations and delay synergies.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance its innovative treatment pipeline.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

INACTIVE